Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 4:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 471 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Human Papillomavirus Virus Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Gardasil in Mid-Adult Males (MAM)

NCT01432574
View directory record Official record
Conditions
Human Papillomavirus
Interventions
Gardasil
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
27 Years to 45 Years · Male only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2021 · Synced Sep 17, 2026, 4:39 AM EDT
Completed Not applicable Interventional

TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck

NCT03729518
View directory record Official record
Conditions
Oropharyngeal Cancer, Squamous Cell Carcinoma, Human Papilloma Virus
Interventions
Radiation Therapy (IMRT or IMPT)
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 17, 2026, 4:39 AM EDT
Terminated Not applicable Interventional

Conversational Agents to Improve HPV Vaccine Acceptance in Primary Care (ECA-HPV)- Clinical Trial

NCT06367699
View directory record Official record
Conditions
Human Papilloma Virus
Interventions
Usual Care, ECA-HPV App with Clinic Notification and Adolescent Functions Disabled, ECA-HPV App with Clinic Notification Function Enabled, ECA-HPV App with Adolescent Function Enabled, ECA-HPV App with Clinic Notification and Adolescent Functions Enabled
Behavioral
Lead sponsor
Tufts Medical Center
Other
Eligibility
8 Years to 12 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Sep 17, 2026, 4:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Culturally Tailored HPV Psychoeducational Multimedia Intervention

NCT06098690
View directory record Official record
Conditions
Health Knowledge, Attitudes, Practice, Vaccine-Preventable Diseases, Intention, Adherence, Patient
Interventions
Culturally Tailored Multimedia Psychoeducational HPV Intervention, General HPV Multimedia Psychoeducational Control Group
Behavioral
Lead sponsor
University of Texas, El Paso
Other
Eligibility
18 Years to 45 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 17, 2026, 4:39 AM EDT
Terminated Phase 2 Interventional

Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma

NCT02225496
View directory record Official record
Conditions
Oropharyngeal Cancer
Interventions
Transoral Robotic Surgery (TORS), Modified Barium Swallow (MBS), Questionnaires
Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2017 · Synced Sep 17, 2026, 4:39 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Evaluation of the APTIMA® HPV Assay Using the TIGRIS® System

NCT00973362
View directory record Official record
Conditions
Human Papillomavirus Infection
Interventions
APTIMA HPV Assay, FDA-Approved HPV DNA Test
Device
Lead sponsor
Gen-Probe, Incorporated
Industry
Eligibility
21 Years and older · Female only
Enrollment
12,896 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
17
States / cities
Jonesboro, Arkansas • Canoga Park, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Sep 17, 2026, 4:39 AM EDT
Completed Phase 2 Interventional Results available

Avelumab for People With Recurrent Respiratory Papillomatosis

NCT02859454
View directory record Official record
Conditions
Recurrent Respiratory Papillomatosis, Juvenile Laryngeal Papilloma, Laryngeal Papilloma, Recurrent, Respiratory Papillomatosis, Human Papilloma Virus
Interventions
Avelumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Sep 17, 2026, 4:39 AM EDT
Completed Phase 4 Interventional Results available

Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?

NCT01101750
View directory record Official record
Conditions
Cervical Cancer, Hpv, Warts
Interventions
Quadrivalent HPV for types 6, 11, 16 and 18
Biological
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
9 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 17, 2026, 4:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

MeFirst: A Tailored Intervention to HPV Vaccine Decision Making

NCT01769560
View directory record Official record
Conditions
Human Papillomavirus-Related Carcinoma
Interventions
MeFirst Tailored Intervention
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 26 Years · Female only
Enrollment
661 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 21, 2015 · Synced Sep 17, 2026, 4:39 AM EDT
Terminated Phase 2 Interventional Results available

Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions

NCT03937791
View directory record Official record
Conditions
Squamous Lntraepithelial Lesions of Vulva, Neoplasms, Squamous Cell, Vulvar HSIL
Interventions
E7 T Cell Receptor (TCR)
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Sep 17, 2026, 4:39 AM EDT
Recruiting Phase 2 Interventional

The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial)

NCT05419089
View directory record Official record
Conditions
HPV-positive Oropharyngeal Squamous Cell Carcinoma
Interventions
Robotic surgery
Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
2
States / cities
Paramus, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 17, 2026, 4:39 AM EDT
Recruiting Phase 2 Interventional

De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA

NCT05541016
View directory record Official record
Conditions
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma, Stage I Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Biospecimen Collection, Cisplatin, Computed Tomography, Diffusing Alpha-emitter Radiation Therapy, Docetaxel, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Modified Barium Swallow Study, Observation Activity, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire
Procedure · Drug · Radiation + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 17, 2026, 4:39 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Human Papillomavirus (HPV) Oral Transmission Study in Partners Over Time

NCT01342978
View directory record Official record
Conditions
Oropharyngeal Cancer, Human Papillomavirus
Interventions
Not listed
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 17, 2026, 4:39 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Immunogenicity of Off-Schedule Dosing of HPV Vaccine

NCT01030562
View directory record Official record
Conditions
Papilloma Viral Infection
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
9 Years to 17 Years · Female only
Enrollment
1,321 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
7
States / cities
Tucker, Georgia • Baltimore, Maryland • Kansas City, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2018 · Synced Sep 17, 2026, 4:39 AM EDT
Terminated Phase 2 Interventional Results available

Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer

NCT03258008
View directory record Official record
Conditions
Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx, Oropharyngeal Cancer
Interventions
Utomilumab, ISA101b
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced Sep 17, 2026, 4:39 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Natural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune)

NCT05026138
View directory record Official record
Conditions
Human Papillomavirus
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 100 Years
Enrollment
850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2047
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 17, 2026, 4:39 AM EDT
Terminated Phase 1 Interventional Results available

Immunotherapy With E6 T Cell Receptor (TCR) T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions

NCT03197025
View directory record Official record
Conditions
Human Papillomavirus, HPV-16, High Grade Squamous Intraepithelial Lesion
Interventions
Aldesleukin, E6 T Cell Receptor (TCR)
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 65 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Sep 17, 2026, 4:39 AM EDT
Recruiting Phase 2 Interventional

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

NCT05686226
View directory record Official record
Conditions
Cervical Cancer, Throat Cancer, Oropharynx Cancer, Anal Cancer, Vulva Cancer, Vaginal Cancer, Penile Cancer, Metastatic Cancer, HPV-Related Malignancy, HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Adenocarcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma
Interventions
E7 TCR-T cells, Aldesleukin
Biological · Drug
Lead sponsor
Christian Hinrichs
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Bethesda, Maryland • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 17, 2026, 4:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

PREVENT HPV-Related Cancers - BootCamp Translation

NCT06290206
View directory record Official record
Conditions
HPV Vaccination, Vaccine; Uptake, Vaccination; Series Completion
Interventions
PREVENT - BCT
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced Sep 17, 2026, 4:39 AM EDT
Completed No phase listed Observational

The Effects of Combination Anti-HIV Medication on Human Papillomavirus (HPV) in HIV-Infected Women

NCT00006444
View directory record Official record
Conditions
HIV Infections, Papilloma
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
49
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Sep 17, 2026, 4:39 AM EDT
Active, not recruiting Phase 2 Interventional

Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia

NCT03519464
View directory record Official record
Conditions
Idiopathic CD4 T Cell Lymphocytopenia
Interventions
Gardasil 9
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 17, 2026, 4:39 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety of Anal Curcumin

NCT06626230
View directory record Official record
Conditions
Anal High Grade Squamous Intraepithelial Lesion
Interventions
Curcuminoid Capsules
Drug
Lead sponsor
Lisa Flowers
Other
Eligibility
30 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 17, 2026, 4:39 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Impact of Financial Incentives

NCT05744960
View directory record Official record
Conditions
Human Papilloma Virus
Interventions
Communication training, financial Incentive
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
9 Years to 12 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 17, 2026, 4:39 AM EDT
Completed Phase 3 Interventional Results available

Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer

NCT01302834
View directory record Official record
Conditions
Head and Neck Cancer, Precancerous Condition
Interventions
cetuximab, cisplatin, IMRT
Biological · Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
987 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
183
States / cities
Anchorage, Alaska • Auburn, California • Burbank, California + 152 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 17, 2026, 4:39 AM EDT